Abstract Search

ea0049ep755 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2017

PCSK9 inhibitors effects on lipid profile in familial hypercholesterolemia in a specific Lipid Unit: experience in first year commercialization

Gonzalez-Molero Inmaculada , Doulatram Viyu , Marin Monserrat Gonzalo , Abuin Jose , Morillas Virginia , Olveira Gabriel , Tinahones Francisco

Objective: Analyse the features of first patients treated with PCSK9 inhibitors in a specific Familial dyslipidemia Unit and the effects on lipid profile in first months of treatment.Material and methods: Data from patients with heterozygous familial hypercholesterolemia treated with PCSK9 inhibitors were reviewed. Clinical data, physical examination and analytical data were collected at baseline, one month and 3 months.Results: Da...

0 shares

ea0056gp95 | Diabetes Therapy | ECE2018

Randomized control study to compare security and efficacy of the new long acting analogues degludec and glargina U300 in people with type 1 Diabetes. Preliminary results of the Ineox study

Dominguez-Lopez Marta Elena , Vallejo Rosario , Morillas Virginia , Colomo Natalia , Guerrero Mercedes , Rojo Gema , de Adana Navas Marisol Ruiz

Background: There arent published randomized studies comparing the clinical impact of degludec and Glragina U300 in the treatment of type 1 diabetes patients. (T1DP)Objective: To compare efficacy and safety of the new long acting analogues Glargine U 300 and Degludec in 300 Type1 diabetes patients treated with basal/bolus treatment.(BBT)Material and methods: Randomized control study 1.1 in 300 T1DP treated with BBT with glarg...

0 shares

Endocrine Abstracts

PCSK9 inhibitors effects on lipid profile in familial hypercholesterolemia in a specific Lipid Unit: experience in first year commercialization

Randomized control study to compare security and efficacy of the new long acting analogues degludec and glargina U300 in people with type 1 Diabetes. Preliminary results of the Ineox study

BiosciAbstracts